Please use this identifier to cite or link to this item:
https://hdl.handle.net/1959.11/23012
Title: | A role for autoantibodies in atherogenesis | Contributor(s): | Iseme, Rosebella A (author); McEvoy, Mark (author); Kelly, Brian (author); Agnew, Linda (author) ; Walker, Frederick R (author); Handley, Tonelle (author); Oldmeadow, Christopher (author); Attia, John (author); Boyle, Michael (author) | Publication Date: | 2017 | DOI: | 10.1093/cvr/cvx112 | Handle Link: | https://hdl.handle.net/1959.11/23012 | Abstract: | An increased risk of cardiovascular disease (CVD) has long been recognized amongst people with autoimmune disease. It has been unclear whether this is due mainly to the ensuing treatment, particularly steroids, or whether some of this risk is due to the autoimmune process itself with subsequent inflammation. Indeed, a large body of evidence supports a role for chronic inflammation in atherogenesis, and autoantibodies have been identified as mediators in this complex inflammatory environment. Our aim is to carry out a systematic review of existing literature in order to formally establish the strength of the association between autoantibodies and atherosclerosis, amongst individuals without clinical autoimmune disease. An electronic search of five databases to June 2016 was performed by two independent reviewers. Inclusion criteria were analytical studies of adults, with at least two studies per autoantibody. Quality analysis was carried out using the Newcastle-Ottawa scale and the Cochrane Risk of Bias Quality Assessment Tool where appropriate. Where possible, studies were pooled using random effects models. Raised levels of anti-cardiolipin (odds ratio [OR] = 1.30; 95% CI: 1.15-1.49) and anti-oxidized low-density lipoprotein Immunoglobulin (Ig) G (OR = 1.25; 95% CI: 1.11-1.41), unspecified anti-cyclic citrullinated protein (OR = 3.09; 95% CI: 1.49-6.41) and anti-human heat shock protein 60 IgA (OR = 1.57; 95% CI: 1.15-2.16) were observed to increase the risk of cardiovascular outcomes. Alternatively, Anti-phosphorylcholine IgM (OR = 1.31; 95% CI: 1.14-1.50) conferred protection against CVD. Our results support an important role for autoantibodies in mediating cardiovascular events, independent of therapeutic treatments. Future research may focus on the presence of autoantibodies as markers of immune dysregulation and CVD risk. | Publication Type: | Journal Article | Source of Publication: | Cardiovascular Research, 113(10), p. 1102-1112 | Publisher: | Oxford University Press | Place of Publication: | United Kingdom | ISSN: | 1755-3245 0008-6363 |
Fields of Research (FoR) 2008: | 110201 Cardiology (incl. Cardiovascular Diseases) | Fields of Research (FoR) 2020: | 320101 Cardiology (incl. cardiovascular diseases) | Socio-Economic Objective (SEO) 2008: | 920103 Cardiovascular System and Diseases | Socio-Economic Objective (SEO) 2020: | 200101 Diagnosis of human diseases and conditions | Peer Reviewed: | Yes | HERDC Category Description: | C1 Refereed Article in a Scholarly Journal |
---|---|
Appears in Collections: | Journal Article School of Rural Medicine School of Science and Technology |
Files in This Item:
File | Description | Size | Format |
---|
SCOPUSTM
Citations
62
checked on Oct 26, 2024
Page view(s)
2,400
checked on Mar 31, 2024
Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.